New antibody fragments light up tumors in early imaging trial

NCT ID NCT06645808

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-phase trial is testing two new antibody fragments that are designed to attach to a sugar molecule found on many solid tumors. The fragments are labeled with a radioactive tracer so they can be seen on PET/CT scans. The study aims to see where these fragments go in the body, how safe they are, and whether they can help spot tumors more clearly. About 32 adults with various solid tumors will take part.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
89Zr-DFO-N-Suc-F8scFv and 89Zr-DFO-N-Suc-C9scFv (radiolabeled antibody fragments)
What this could lead to
If successful, this could pave the way for better imaging and targeted treatments for many solid tumor types.
What could go wrong
This is a very early phase 0 trial with only 32 participants, so results may not apply broadly. The main goal is imaging, not treatment, so direct patient benefit is unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Medical Center Groningen (UMCG)

    RECRUITING

    Groningen, Provincie Groningen, 9713GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.